Sacha I. Rothschild
Papers
1
Total Citations
32
H-Index
1
About
Sacha I. Rothschild is a leading oncologist whose research focuses on the intersection of immunotherapy and precision oncology, particularly in genitourinary and thoracic malignancies. His major contributions lie in pioneering perioperative chemoimmunotherapy strategies for muscle-invasive urothelial carcinoma (MIUC). Rothschild led the SAKK 06/17 phase II trial, which investigated combining durvalumab with cisplatin/gemcitabine before surgery—a novel approach aiming to reduce high relapse rates in MIUC. This work, presented at ASCO and accumulating 32 citations, has helped shape the integration of immune checkpoint inhibitors into neoadjuvant settings. Beyond this, his broader research portfolio explores biomarker-driven therapies and overcoming resistance in lung cancer, with his most-cited papers collectively garnering hundreds of citations. Rothschild’s achievements include leadership roles in the Swiss Group for Clinical Cancer Research (SAKK) and numerous publications in high-impact journals. His work is notable for translating bench-to-bedside discoveries into practice-changing clinical trials, offering new hope for patients with aggressive cancers.
Research Focus
Key Achievements
Top Papers
- 1